GLAND PHARMA LIMITED

August 10, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Press Release on Q1FY27 Financial Results

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find enclosed the Press Release on Q1FY27 Financial Results.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Pallerlamudi Sampath Kumar

Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.08.10 16:25:14 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: As above

Press Release

Gland Pharma Reports Yet Another Quarter with Record Revenues

Revenue Growth @ 20% Y-o-Y | PAT Growth @ 47% Y-o-Y

Hyderabad, August 10th, 2026: Gland Pharma Limited (BSE: 543245 | NSE: GLAND), an injectable-focused pharmaceutical company, announced its financial results for the first quarter and year ended June 30th, 2026.

Commenting on the results, **Mr. Srinivas Sadu, Executive Chairman of Gland Pharma**, stated, ***"Our strong start to FY27 reflects the successful execution of our CDMO strategy and the resilience of our B2B business model. Growth was driven by recent product launches from CDMO portfolio and strong customer demand for our diversified product mix. We continue to strengthen our growth platform through a robust CDMO pipeline including investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth."***

Consolidated Financial Performance

₹ Mn

Particulars	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	18,003	15,056	20%	17,428	3%
Gross Profit(1)	11,759	9,845	19%	11,515	2%
Gross Profit margin (%)	65%	65%		66%	
EBITDA(2)	4,930	3,678	34%	5,130	-4%
EBITDA margin (%)(3)	27%	24%		29%	
Adj. EBITDA(4)	5,102	3,737	37%	5,244	-3%
Adj. EBITDA margin (%)	28%	25%		30%	
PBT	4,350	3,127	39%	5,058	-14%
PBT margin (%)	24%	21%		29%	
PAT	3,170	2,155	47%	3,667	-14%
PAT margin (%)	18%	14%		21%	

1. Gross Profit = Revenue from Operations – Materials consumed; 2. EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense excluding other income and forex losses. 3. EBITDA margin = EBITDA / Revenue from operations; 4.Adj. EBITDA = EBITDA plus Employee stock option compensation expenses.

Financial Highlights:

- Quarterly revenue increased by 20% year-on-year.
- Quarterly R&D investments stood at ₹ 772 million.
- Quarterly adj. EBITDA increased by 37% year-on-year.
- Quarterly adj. EBITDA margin stood at 28%.
- Quarterly PAT increased by 47% year-on-year.
- Quarterly PAT margin increased by ~330 bps year-on-year.
- CDMO business contributed 50% of revenues and grew by 20% year-on-year in Q1FY27.
- B2B* business contributed 50% of revenues and grew by 19% year-on-year in Q1FY27.

** Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.*

Business-wise Performance

₹ Mn

Business	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
CDMO	8,915	7,411	20%	8,059	11%
B2B*	9,088	7,645	19%	9,369	-3%
Total	**18,003**	**15,056**	**20%**	**17,428**	**3%**

** Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.*

Market-wise Performance

₹ Mn

Markets	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
USA	9,810	7,443	32%	9,807	0%
Europe	3,954	3,302	20%	3,814	4%
Canada, Australia and New Zealand *(Other Core Markets)*	534	739	-28%	588	-9%
India	666	594	12%	670	-1%
Rest of the world	3,039	2,978	2%	2,549	19%
TOTAL	**18,003**	**15,056**	**20%**	**17,428**	**3%**

Business Highlights:

- **R&D Expenses:** Total R&D expenses were ₹772 million in Q1 FY27, representing 4% of consolidated revenue. The R&D expenditure was mainly focused on complex product development and the number of filings.
- **New Launches:** The company launched 4 molecules in the USA this quarter, including Multi-Vitamin and Leucovorin calcium.
- **Filings and Approvals:** Three ANDAs were filed, and seven were approved in Q1 FY27, contributing to a cumulative total of 389 ANDA filings in the U.S. (342 approved, 47 pending).
- **In-house Complex Pipeline:** Six products have already been launched, and three more are in line for approval. Complex injectables are expected to remain a central pillar of long-term growth, with more products being added to the pipeline.
- **Co-development Partnerships:** Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercialization anticipated to begin in FY28.
- **Ready-to-Use (RTU) Bags:** Filed 21 Ready-to-Use infusion bag products and received approval for 18 so far. An additional 11 are currently under development. The total RTU bag portfolio addresses a market opportunity of approximately $644 million in the US.
- **CDMO partnership with A Global Pharmaceutical Company:** Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029.
- **Strategic collaboration with Neuland Laboratories**: Long-term strategic collaboration for the manufacturing of sterile APIs for microparticle depot products.
- **In-licensing agreement with a China-based development company** for the development, manufacturing and commercialization of a niche liposomal product for the U.S. and European markets.

Earnings Call Details

The Company will conduct an Earnings call at 6.30 PM (IST) on August 10th, 2026, to discuss the business performance and answer participants' questions. To participate in this conference call, please dial the numbers provided below ten minutes before the scheduled start time.

Universal Access	**+91 22 6280 1516 / +91 22 7115 8875**
Diamond pass link	Click ***here*** to register
National Toll-Free	1 800 120 1221
International Toll-Free Number	USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448

About Gland Pharma Limited (BSE: 543245, NSE: GLAND)

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a Contract Development & Manufacturing Operations (CDMO), Business-to-Business (B2B) model and has an excellent track record in the development, manufacturing, and marketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, and also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: www.glandpharma.com

Investor Contacts

Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Shriniwas P. Dange
Investor Relations
investors@glandpharma.com